| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT06917911 Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment… |
Trial sites expanded: 7 -> 14 locations |
| 2026-06-12 | NCT04847453 Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or… |
date change Primary completion pushed: 2026-06-30 -> 2028-06-30 |
| 2026-06-12 | NCT04847453 Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or… |
date change Completion pushed: 2026-06-30 -> 2028-06-30 |
| 2026-06-12 | NCT03041688 Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and… |
date change Primary completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-12 | NCT03041688 Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and… |
date change Completion pushed: 2026-06-30 -> 2027-06-30 |
| 2026-06-10 | NCT07490288 Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML |
Recruitment opened |
| 2026-06-10 | NCT07490288 Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML |
Primary endpoint(s) modified |
| 2026-06-10 | NCT07490288 Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML |
Enrollment reduced: 30 -> 27 participants |
| 2026-06-09 | NCT07200102 Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma |
Primary endpoint(s) modified |
| 2026-06-06 | NCT05053659 Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma |
date change Primary completion pushed: 2026-06 -> 2026-11 |
| 2026-06-06 | NCT05053659 Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma |
date change Completion pushed: 2026-06 -> 2026-11 |
| 2026-06-06 | NCT04550442 Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk… |
Trial terminated |
| 2026-06-06 | NCT04550442 Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk… |
critical why stopped: null → "\\<75% participation" |
| 2026-06-06 | NCT04550442 Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk… |
date change Primary completion pushed: 2026-03-31 -> 2026-05-29 |
| 2026-06-06 | NCT04550442 Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk… |
date change Completion pushed: 2026-03-31 -> 2026-05-29 |
| 2026-06-06 | NCT04188405 Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia… |
Trial completed |
| 2026-06-06 | NCT04188405 Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia… |
date change Primary completion moved earlier: 2026-11-30 -> 2026-06-02 |
| 2026-06-06 | NCT04188405 Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia… |
date change Completion moved earlier: 2026-11-30 -> 2026-06-02 |
| 2026-06-04 | NCT05091424 A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a… |
date change Primary completion pushed: 2028-05-31 -> 2031-02-10 |
| 2026-06-04 | NCT05091424 A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a… |
date change Completion pushed: 2030-02-28 -> 2032-02-10 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-11 | NCT07643103 Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative… | Phase 2 | Not Yet Recruiting |
| 2026-06-09 | NCT07635485 VA Induction and Bridging Transplantation for Hypoplastic/Secondary AML | Not Yet Recruiting | |
| 2026-06-08 | NCT07632170 The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the… | Not Yet Recruiting | |
| 2026-06-04 | NCT07626021 Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms | Phase 2 | Not Yet Recruiting |
| 2026-05-26 | NCT07605949 Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML | Phase 2 | Not Yet Recruiting |
| 2026-05-22 | NCT07604233 Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML | Phase 1/2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT07044687 | Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in… | Acute Myeloid Leukemia | Recruiting |
| Phase 3 | |||
| NCT07132684 | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia… | AML, Adult | Recruiting |
| NCT06428019 | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT05712694 | Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With… | Soft Tissue Sarcoma | Recruiting |
| NCT05947851 | A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line… | Leukemia, Lymphocytic, Chronic, B-Cell | Recruiting |
| NCT05183035 | Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | Recruiting |
| NCT07138209 | A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or… | Relapsed or Refractory Multiple Myeloma | Recruiting |
| NCT04628026 | Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients… | Acute Myeloid Leukemia | Recruiting |
| NCT06846671 | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic… | CLL | Recruiting |
| NCT07007312 | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With… | Acute Myeloid Leukemia (AML) | Recruiting |
| NCT07277231 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06943872 | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT06852222 | A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With… | Leukemia, Myeloid, Acute | Recruiting |
| NCT06158841 | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard… | Multiple Myeloma | Recruiting |
| NCT04269902 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT04965493 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT07407660 | Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in… | Acute Myeloid Leukemia | Not Yet Recruiting |
| NCT03336333 | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With… | Chronic Lymphocytic Leukemia | Active, Not Recruiting |
| NCT07478991 | Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients… | Acute Myeloid Leukemia, Adult | Not Yet Recruiting |
| NCT07486479 | Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and… | Acute Myeloid Leukemia (AML) | Not Yet Recruiting |
| NCT04562389 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | Myelofibrosis | Active, Not Recruiting |
| NCT07469046 | VAH vs VA in Newly Diagnosed Elderly AML | Acute Myeloid Leukemia (AML) | Not Yet Recruiting |
| NCT07539818 | Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML | AML | Not Yet Recruiting |
| NCT03768063 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd… | Cancer | Active, Not Recruiting |
| NCT04608318 | Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus… | Chronic Lymphoid Leukemia | Active, Not Recruiting |